

Supporting Information
for DOI: 10.1055/a-1315-1279

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany

Supporting Online Material for

Facile Pyridine S_NAr Reactions via *N*-Phosphonium Pyridinium Intermediates

Benjamin T. Boyle, J. Luke Koniarczyk and Andrew McNally*

Department of Chemistry, Colorado State University,
Fort Collins, Colorado 80523, United States.

*andy.mcnally@colostate.edu

Table of Contents

1. General Information	<i>S2</i>
2. Optimization Studies	<i>S4</i>
3. Iodine Spiking Studies	<i>S6</i>
4. Challenges and Limitations	<i>S9</i>
5. Preparation of Heteroaryl Phosphoniums	<i>S10</i>
6. References	<i>S19</i>
7. 1H, ^{13}C, ^{19}F and ^{31}P Spectra	<i>S20</i>

1. General Information

Proton nuclear magnetic resonance (^1H NMR) spectra were recorded at ambient temperature on either a Bruker Ultrashield-400 (400 MHz) spectrometer, a Varian 400 MR (400 MHz) spectrometer or an Agilent Inova 400 (400 MHz) spectrometer. Chemical shifts (δ) are reported in ppm and quoted to the nearest 0.01 ppm relative to the residual protons in CDCl_3 (7.26 ppm), C_6D_6 (7.16 ppm), $(\text{CD}_3)_2\text{SO}$ (2.50 ppm), CD_3OD (3.31 ppm) or CD_3CN (1.94 ppm) and coupling constants (J) are quoted in Hertz (Hz). Data are reported as follows: Chemical shift (multiplicity, coupling constants, number of protons). Coupling constants were quoted to the nearest 0.1 Hz and multiplicity reported according to the following convention: s = singlet, d = doublet, t = triplet, q = quartet, qn = quintet, sext = sextet, sp = septet, m = multiplet, br = broad. Carbon nuclear magnetic resonance (^{13}C NMR) spectra were recorded at ambient temperature on either a Bruker Ultrashield-400 (400 MHz) spectrometer, a Varian 400 MR spectrometer (100 MHz) or an Agilent Inova 400 (100 MHz) spectrometer. Chemical shift (δ) was measured in ppm and quoted to the nearest 0.1 ppm relative to the residual solvent peaks in CDCl_3 (77.16 ppm), C_6D_6 (128.06 ppm), $(\text{CD}_3)_2\text{SO}$ (39.51 ppm), CD_3OD (49.00 ppm) or CD_3CN (1.32 ppm). DEPT135, NOE experiments and 2-dimensional experiments (COSY, HMBC, and HSQC) were used to support assignments where appropriate.

Low-resolution mass spectra (LRMS) were measured on an Agilent 6310 Quadrupole Mass Spectrometer.

Analytical thin layer chromatography (TLC) was performed using pre-coated Merck glass backed silica gel plates (Silicagel 60 F254). Flash column chromatography was undertaken on Fluka or Material Harvest silica gel (230–400 mesh) under a positive pressure of air. Visualization was achieved using ultraviolet light (254 nm) and chemical staining with ceric ammonium molybdate or basic potassium permanganate solutions as appropriate.


Tetrahydrofuran (THF), toluene, hexane, diethyl ether and dichloromethane were dried and distilled using standard methods.¹ Chloroform (CHCl_3) was purchased anhydrous from Sigma Aldrich chemical company. All reagents were purchased at the highest commercial quality and used without further purification. Reactions were carried out under an atmosphere of air unless otherwise stated. All reactions were monitored by TLC, ^1H NMR spectra taken from reaction

samples, gas chromatography (GC) and gas chromatography–mass spectrometry (GCMS) using an Agilent 5977A fitted with an Agilent J&W HP–5ms Ultra Inert Column (30 m, 0.25 mm, 0.25 μm film) for MS analysis and an Agilent J&W VF–5ms column (10 m, 0.15 mm, 0.15 μm film) for FID analysis or liquid chromatography mass spectrometry (LCMS) using an Agilent 6310 Quadrupole Mass Spectrometer. Melting points (mp) were recorded using a Büchi B–450 melting point apparatus and are reported uncorrected.

Tri-p-anisole phosphine (99%) was purchased from Oakwood Chemicals and stored in a glovebox. Tri-p-anisole phosphine was commonly dispensed into vials for use in the reaction and stored under air on a benchtop prior to use. Anhydrous chloroform (0.05-0.1% EtOH as stabilizer) was purchased from Sigma Aldrich chemical company and used without further purification

2. Optimization Studies


Table S1: Phosphine Screen at 50 °C



Entry	Phosphine	Yield (%)*
1	PPh_3	79
2	$(p\text{-Cl})\text{Ph}_3\text{P}$	4
3	$(\text{thienyl})_3\text{P}$	15
4	$(p\text{-tol})_3\text{P}$	97
5	$(o\text{-tol})_3\text{P}$	2
6	$n\text{Bu}_3\text{P}$	56
7	$(p\text{-OMe})\text{Ph}_3\text{P}$	97
8	Ph_2PEt	99


* ^1H NMR yields shown using triphenylmethane as an internal standard.

Table S2: Phosphine Screen: Room Temperature




Entry	Phosphine	Yield (%)*
1	Ph_3P	6
2	$n\text{Bu}_3\text{P}$	5
3	PEt_3	8
4	PhPEt_2	79
5	Ph_2PEt	86
6	$(p\text{-tol})_3\text{P}$	78
8	$(p\text{-OMe})\text{Ph}_3\text{P}$	86

* ^1H NMR yields shown using triphenylmethane as an internal standard.

Table S3: Phosphonium Formation Additive Screen

Entry	Conditions/Additive	Yield (%)*
1	H ₂ O (10 eq)	83
2	Cs ₂ CO ₃	n.d.†
3	MeOH‡	n.d.†
4	Light excluded	83
5	Sublimed Iodopyridine	66
6	Standard	87


*¹H NMR yields shown using triphenylmethane as an internal standard. †Products were not detected by LCMS or ¹H NMR. ‡MeOH was used as the solvent instead of CH₂Cl₂.

Table S4: AIBN Study: Radical Initiator -Shortened Reaction Times


Entry	Additive	Yield (%)*
1	None	23
2	AIBN (5 mol%)	22
3	AIBN (10 mol%)	24
4	AIBN (25 mol%)	24

*¹H NMR yields shown using triphenylmethane as an internal standard. No increase in reaction rate was observed using AIBN as a radical initiator, this experiment was ran at 50 °C and 80 °C with no observable increase in reaction rate.


3. Iodine Spiking Studies



Scheme S1: ¹H NMR and ³¹P NMR: I₂ addition to (p-anisole)Ph₃P. Show reaction and shifting of phosphine peaks as iodine concentration increase. Consistent with reports of I⁺PAR₃ formation.




Scheme S2: ¹H NMR: I₂ addition to (p-anisole)Ph₃P with 1 equivalent of pyridine. Show reaction and shifting of phosphine peaks as iodine concentration increase. Consistent with formation of an activated pyridinium species, in particular meta position proton shift 7.3 to 7.5 ppm and para position shift from 7.7 to 7.85 ppm.






Scheme S3: ¹H NMR: I₂ addition to pyridine. Known reactivity to form activated pyridines. Shows distinct peaks when compared to Scheme S3 indicating species observed under reaction conditions are not associated with an iodo-pyridinium.

4. Challenges and Limitations




What doesn't work:



5. Preparation of Heteroaryl Phosphonium Salts

General Procedure A:




An oven dried 8 mL vial (< 1.0 mmol) or 16 mL vial (1.0-4.0 mmol) equipped with a stir bar was charged with the iodopyridine (1.0 equiv) and $(\text{p-anisole})_3\text{P}$ (1.0 equiv) and CHCl_3 (0.5 M). The reaction was then stirred at the temperature indicated (rt, 50 °C or 80 °C) for the stated time. The reaction was then purified by diluting the crude reaction with CHCl_3 and by crashing out in Et_2O (100 mL per 1.0 mmol) at room temperature.

Notes:


1. Reaction was ran under air and N_2 atmospheres and no notable differences in yields were observed.
2. Additional phosphine can be used to increase the reaction rate (1st order in phosphine)
3. In general the reaction does not product by-products besides trace phosphine oxide.

(3-Chloropyridin-4-yl)tris(4-methoxyphenyl)phosphonium iodide (1b)




Prepared according to general procedure A using 3-chloro-4-iodopyridine (72 mg, 0.30 mmol), tris(4-methoxyphenyl)phosphane (106 mg, 0.30 mmol), and chloroform (0.6 mL) at room temperature for 36 hours. After purification procedure, the title compound was isolated as a light brown solid (174 mg, 0.3 mmol, 98% yield). mp 91-93 °C; ^1H NMR (400 MHz, CDCl_3) δ : 9.12 – 8.59 (m, 2H), 7.58 (dd, $J=12.7, 8.9$, 6H), 7.48 – 7.10 (m, 7H), 3.95 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ : 165.40 (d, $J=3.0$), 151.98 (d, $J=5.0$), 150.11 (d, $J=9.8$), 136.35 (d, $J=12.4$), 134.75 (d, $J=2.2$), 130.32 (d, $J=8.4$), 129.29 (d, $J=88.3$), 117.02 (d, $J=14.5$), 105.78 (d, $J=100.0$), 56.51; ^{31}P NMR (162 MHz, CDCl_3) δ : 21.08; m/z LRMS (ESI + APCI) found $[\text{M-I}]^+$ 464.2, $\text{C}_{26}\text{H}_{24}\text{ClNO}_3\text{P}^+$ requires 464.1.

Tris(4-methoxyphenyl)(3-(trifluoromethyl)pyridin-4-yl)phosphonium iodide (1c)




Prepared according to general procedure A using 4-iodo-3-(trifluoromethyl)pyridine (27 mg, 0.10 mmol), tris(4-methoxyphenyl)phosphane (35 mg, 0.10 mmol), and chloroform (0.2 mL) at room temperature for 37 hours. After purification procedure, the title compound was isolated as a yellow solid (53 mg, 0.09 mmol, 85% yield). mp 93-96 °C. ^1H NMR (400 MHz, CDCl_3) δ : 9.26 (m, 2H), 7.72 – 7.56 (m, 7H), 7.26 (m, 6H), 3.97 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ : 165.41 (d, $J=3.0$), 156.20 (d, $J=9.5$), 150.29, 150.21 (d, $J=5.2$), 136.67 (d, $J=12.3$), 131.24 (d, $J=8.9$), 122.51 (qd, $J=273.2, 2.7$), 116.80 (d, $J=14.6$), 106.96 (d, $J=99.9$), 56.4; ^{19}F NMR (365 MHz, CDCl_3) δ : -54.14 (d, $J=2.1$); ^{31}P NMR (162 MHz, CDCl_3) δ : 25.27; m/z LRMS (ESI + APCI) found $[\text{M-I}]^+$ 498.2, $\text{C}_{27}\text{H}_{24}\text{F}_3\text{NO}_3\text{P}^+$ requires 498.1.

(3-Aminopyridin-4-yl)tris(4-methoxyphenyl)phosphonium iodide (1d)




Prepared according to general procedure A using 4-iodopyridin-3-amine (66 mg, 0.30 mmol), tris(4-methoxyphenyl)phosphane (106 mg, 0.30 mmol), and chloroform (0.6 mL) at 50 °C for 19 hours. After purification procedure, the title compound was isolated as a dark red crystalline solid (163 mg, 0.29 mmol, 95% yield). mp 148-151 °C; IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3048, 3001, 2961, 1576, 1555, 1443, 1433, 1094, 796, 754, 698; ^1H NMR (400 MHz, CD_3CN) δ : 8.46 (d, $J=7.3$, 1H), 7.99 (dd, $J=5.3, 3.4$, 1H), 7.74 – 7.48 (m, 6H), 7.24 (dd, $J=9.0, 2.7$, 6H), 6.76 (dd, $J=15.4, 5.4$, 1H), 4.85 (s, 2H), 3.92 (s, 9H); ^{13}C NMR (100 MHz, CD_3CN) δ : 166.18 (d, $J=2.9$), 147.39 (d, $J=3.5$), 141.32 (d, $J=5.9$), 138.31 (d, $J=10.8$), 137.39 (d, $J=12.4$), 134.47 (d, $J=11.1$), 128.00 (d, $J=8.6$), 117.20 (d, $J=14.2$), 107.65 (d, $J=98.0$), 56.8; ^{31}P NMR (162 MHz, CDCl_3) δ : 17.57; m/z LRMS (ESI + APCI) found $[\text{M-I}]^+$ 445.3, $\text{C}_{26}\text{H}_{26}\text{N}_2\text{O}_3\text{P}^+$ requires 445.2.

(3-Hydroxypyridin-4-yl)tris(4-methoxyphenyl)phosphonium iodide (1e)




Prepared according to general procedure A using 4-iodopyridin-3-ol (66 mg, 0.30 mmol), tris(4-methoxyphenyl)phosphane (106 mg, 0.30 mmol), and chloroform (0.6 mL) at 50 °C for 19 hours. After purification procedure, the title compound was isolated as a yellow solid (169 mg, 0.29 mmol, 99% yield). mp 123 °C; ¹H NMR (400 MHz, CDCl₃) δ: 8.79 (d, *J*=6.5, 1H), 8.09 (dd, *J*=5.2, 3.7, 1H), 7.50 (dd, *J*=12.7, 8.9, 6H), 7.15 (dd, *J*=9.0, 2.7, 6H), 6.90 (dd, *J*=14.6, 5.2, 1H), 3.91 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ: 164.81 (d, *J*=2.9), 159.17, 140.97, 136.05 (d, *J*=12.4), 133.87 (d, *J*=11.8), 127.72 (d, *J*=8.0), 116.24 (d, *J*=14.5), 114.31 (d, *J*=13.5), 108.13 (d, *J*=100.0), 56.2; ³¹P NMR (162 MHz, CDCl₃) δ: 19.74; *m/z* LRMS (ESI + APCI) found [M-I]⁺ 446.2, C₂₆H₂₅NO₄P⁺ requires 446.2

(3,5-Dimethylpyridin-4-yl)tris(4-methoxyphenyl)phosphonium iodide (1f)




Prepared according to general procedure A using 4-iodo-3,5-dimethylpyridine (70 mg, 0.30 mmol), tris(4-methoxyphenyl)phosphane (106 mg, 0.30 mmol), and chloroform (0.6 mL) at 80 °C for 19 hours. After purification procedure, the title compound was isolated as a red crystalline solid (175 mg, 0.3 mmol, 99% yield). mp 122-124 °C; ¹H NMR (400 MHz, CDCl₃) δ: 8.50 (d, *J*=6.0, 2H), 7.68 – 7.55 (m, 6H), 7.28 – 7.23 (m, 7H), 3.94 (s, 9H), 1.83 (d, *J*=1.1, 6H); ¹³C NMR (100 MHz, CDCl₃) δ: 165.16 (d, *J*=3.0), 152.49 (d, *J*=8.5), 137.55 (d, *J*=7.6), 136.14 (d, *J*=12.2), 126.41 (d, *J*=81.8), 117.09 (d, *J*=14.2), 109.34 (d, *J*=95.7), 56.51, 21.08 (d, *J*=5.2); ³¹P NMR (162 MHz, CDCl₃) δ: 15.33; *m/z* LRMS (ESI + APCI) found [M-I]⁺ 458.3, C₂₈H₂₉NO₃P⁺ requires 458.2.

Tris(4-methoxyphenyl)(2-oxo-1,2-dihydropyridin-4-yl)phosphonium iodide (1g)




Prepared according to general procedure A using 4-iodopyridin-2-ol (66 mg, 0.30 mmol), tris(4-methoxyphenyl)phosphane (106 mg, 0.30 mmol), and chloroform (0.6 mL) at 50 °C for 19 hours. After purification procedure, the title compound was isolated as a brown solid (160 mg, 0.29 mmol, 98% yield). mp 78-80 °C; ¹H NMR (400 MHz, CDCl₃) δ: 8.13 (s, 1H), 7.54 (dd, *J*=12.5, 8.5, 6H), 7.25 – 7.18 (m, 6H), 7.13 (d, *J*=6.7, 1H), 7.08 (d, *J*=1.6, 1H), 6.67 – 6.55 (m, 2H), 6.30 (s, 1H), 3.95 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ: 165.53 (d, *J*=2.9), 139.50 (d, *J*=14.1), 136.44 (d, *J*=12.0), 135.43 (d, *J*=79.6), 134.30, 129.62 (d, *J*=8.1), 116.87 (d, *J*=14.2), 105.81 (d, *J*=10.3), 105.80, 56.4; ³¹P NMR (162 MHz, CDCl₃) δ: 20.74; *m/z* LRMS (ESI + APCI) found [M-I]⁺ 446.2, C₂₆H₂₅NO₄P⁺ requires 446.2.

Tris(4-methoxyphenyl)(1H-pyrrolo[2,3-b]pyridin-4-yl)phosphonium iodide (1h)




Prepared according to general procedure A using 4-iodo-1H-pyrrolo[2,3-b]pyridine (73 mg, 0.30 mmol), tris(4-methoxyphenyl)phosphane (106 mg, 0.30 mmol), and chloroform (0.6 mL) at 50 °C for 19 hours. After purification procedure, the title compound was isolated as a yellow solid (156 mg, 0.26 mmol, 87% yield). mp 131 °C; ¹H NMR (400 MHz, CDCl₃) δ: 11.66 (s, 1H), 8.55 (t, *J*=4.7, 1H), 7.85 (t, *J*=2.9, 1H), 7.50 (dd, *J*=12.5, 8.9, 6H), 7.18 (dd, *J*=9.0, 2.7, 6H), 6.98 (dd, *J*=14.8, 4.9, 1H), 5.63 (d, *J*=3.5, 1H), 3.92 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ: 165.15 (d, *J*=2.9), 148.35 (d, *J*=11.6), 142.84 (d, *J*=11.4), 136.20 (d, *J*=12.1), 131.61, 121.71 (d, *J*=8.8), 120.82 (d, *J*=9.1), 118.42 (d, *J*=88.1), 116.60 (d, *J*=14.2), 107.66 (d, *J*=98.1), 100.09 (d, *J*=3.0), 56.37; ³¹P NMR (162 MHz, CDCl₃) δ: 18.33; *m/z* LRMS (ESI + APCI) found [M-I]⁺ 469.3, C₂₈H₂₆N₂O₃P⁺ requires 469.2.

Tris(4-methoxyphenyl)(2-(4-(trifluoromethyl)phenyl)pyridin-4-yl)phosphonium iodide (1i)



Prepared according to general procedure A using 4-iodo-2-(4-(trifluoromethyl)phenyl)pyridine (35 mg, 0.10 mmol), tris(4-methoxyphenyl)phosphane (35 mg, 0.10 mmol), and chloroform (0.2 mL) at 50 °C for 18 hours. After purification procedure, the title compound was isolated as a yellow amorphous solid (62 mg, 0.09 mmol, 89% yield). ¹H NMR (400 MHz, CDCl₃) δ: 9.08 (td, *J*=5.0, 0.9, 1H), 8.10 – 8.04 (m, 2H), 7.83 (ddd, *J*=13.6, 1.6, 0.9, 1H), 7.74 – 7.66 (m, 2H), 7.58 (dd, *J*=12.4, 8.9, 7H), 7.29 (dd, *J*=9.0, 2.8, 6H), 3.95 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ: 165.52 (d, *J*=2.9), 157.68 (d, *J*=10.2), 151.84 (d, *J*=10.6), 140.44, 136.50 (d, *J*=12.1), 132.10 (d, *J*=85.2), 131.95 (d, *J*=32.7), 127.86, 126.23 (d, *J*=8.1), 126.09 (q, *J*=3.8), 123.90 (q, *J*=272.5), 123.52 (d, *J*=8.8), 117.04 (d, *J*=14.2), 106.13 (d, *J*=98.6), 56.52; ¹⁹F NMR (365 MHz, CDCl₃) δ: -62.76; ³¹P NMR (162 MHz, CDCl₃) δ: 20.80; *m/z* LRMS (ESI + APCI) found [M-I]⁺ 574.3, C₃₃H₂₈F₃NO₃P⁺ requires 574.2.


(2-(2,5-Difluorophenyl)-3-methylpyridin-4-yl)tris(4-methoxyphenyl)phosphonium iodide (1j)



Prepared according to general procedure A using 2-(2,5-difluorophenyl)-4-iodo-3-methylpyridine (99 mg, 0.30 mmol), tris(4-methoxyphenyl)phosphane (106 mg, 0.30 mmol), and chloroform (0.6 mL) at 50 °C for 21 hours. After purification procedure, the title compound was isolated as a white solid (171 mg, 0.25 mmol, 83% yield). mp 112 °C; ¹H NMR (400 MHz, CDCl₃)


δ : 8.82 (t, $J=4.5$, 1H), 7.59 (dd, $J=12.5$, 8.9, 6H), 7.40 – 7.25 (m, 7H), 7.21 – 7.03 (m, 3H), 3.94 (s, 9H), 1.91 (s, 3zH); ^{13}C NMR (100 MHz, CDCl_3) δ : 165.30 (d, $J=3.0$), 158.86 (dd, $J=244.9$, 2.2), 156.54 (d, $J=2.4$), 156.60 – 156.33 (m), 154.13 (d, $J=2.6$), 148.96 (d, $J=11.6$), 136.14 (d, $J=12.1$), 130.02 (d, $J=84.0$), 128.48 (d, $J=10.5$), 127.95 (ddd, $J=18.4$, 8.0, 2.4), 118.25 – 117.76 (m), 117.88 (d, $J=24.1$), 117.14 (d, $J=14.2$), 116.90 (d, $J=8.6$), 106.84 (d, $J=97.9$), 56.52, 19.93; ^{19}F NMR (365 MHz, CDCl_3) δ : -116.86 – -117.90 (m), -120.61 – -122.10 (m); ^{31}P NMR (162 MHz, CDCl_3) δ : 20.32; m/z LRMS (ESI + APCI) found $[\text{M-I}]^+$ 556.3, $\text{C}_{33}\text{H}_{29}\text{F}_2\text{NO}_3\text{P}^+$ requires 556.2.

(3-Carboxy-2-chloropyridin-4-yl)tris(4-methoxyphenyl)phosphonium iodide (1k)



Prepared according to general procedure A using 2-chloro-4-iodonicotinic acid (85 mg, 0.30 mmol), tris(4-methoxyphenyl)phosphane (106 mg, 0.30 mmol), and chloroform (0.6 mL) at 50 °C for 19 hours. After purification procedure, the title compound was isolated as a yellow solid (136 mg, 0.27 mmol, 89% yield). mp 95-98 °C; ^1H NMR (400 MHz, CDCl_3) δ : 8.61 – 8.57 (m, 1H), 7.58 (dd, $J=12.5$, 9.0, 6H), 7.25 – 7.21 (m, 1H), 7.15 (dd, $J=9.0$, 2.9, 6H), 3.91 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ : 165.05 (d, $J=3.7$), 164.88 (d, $J=3.0$), 162.59 (d, $J=2.8$), 151.07 (d, $J=12.5$), 149.73 (d, $J=11.9$), 136.88 (d, $J=12.1$), 130.92 (d, $J=86.4$), 126.90 (d, $J=9.9$), 116.08 (d, $J=14.5$), 108.06 (d, $J=100.0$), 56.21; ^{31}P NMR (162 MHz, CDCl_3) δ : 22.97; m/z LRMS (ESI + APCI) found $[\text{M-I}]^+$ 508.2, $\text{C}_{27}\text{H}_{24}\text{ClNO}_5\text{P}^+$ requires 508.1.


(5-Bromo-2-chloropyridin-4-yl)tris(4-methoxyphenyl)phosphonium iodide (1l)



Prepared according to general procedure A using 5-bromo-2-chloro-4-iodopyridine (96 mg, 0.30 mmol), tris(4-methoxyphenyl)phosphane (106 mg, 0.30 mmol), and chloroform (0.6 mL) at 80 °C for 19 hours. After purification procedure, the title compound was isolated as a golden


yellow solid (201 mg, 0.3 mmol, 99% yield). mp 111-114 °C; ¹H NMR (400 MHz, CDCl₃) δ: 8.75 (d, *J*=5.7, 1H), 7.61 (dd, *J*=12.8, 8.9, 6H), 7.30 – 7.24 (m, 6H), 7.12 (d, *J*=14.1, 1H), 3.95 (s, 10H); ¹³C NMR (100 MHz, CDCl₃) δ: 165.56 (d, *J*=3.0), 154.76 (d, *J*=6.7), 152.76 (d, *J*=13.7), 136.61 (d, *J*=12.4), 134.49 (d, *J*=87.9), 131.87 (d, *J*=10.5), 123.00 (d, *J*=3.5), 117.16 (d, *J*=14.5), 105.14 (d, *J*=100.1), 56.5; ³¹P NMR (162 MHz, CDCl₃) δ: 23.14; *m/z* LRMS (ESI + APCI) found [M-I]⁺ 542.1, C₂₆H₂₃BrClNO₃P⁺ requires 542.0.

Tris(4-methoxyphenyl)(2-oxo-1,2-dihydropyridin-4-yl)phosphonium iodide (1m)



Prepared according to general procedure A using 3-(allyloxy)-4-iodopyridine (78 mg, 0.30 mmol), tris(4-methoxyphenyl)phosphane (106 mg, 0.30 mmol), and chloroform (0.6 mL) at room temperature for 36 hours. After purification procedure, the title compound was isolated as a yellow solid (160 mg, 0.30 mmol, 99% yield). mp 71 °C; ¹H NMR (400 MHz, CDCl₃) δ: 8.66 (d, *J*=6.5, 1H), 8.53 (dd, *J*=4.9, 3.6, 1H), 7.54 (dd, *J*=12.8, 8.9, 6H), 7.26 – 7.16 (m, 6H), 7.08 (dd, *J*=14.8, 4.9, 1H), 5.40 (ddd, *J*=16.2, 10.7, 5.4, 1H), 5.09 (dd, *J*=10.5, 1.2, 1H), 5.00 (dd, *J*=17.2, 1.4, 1H), 4.59 (d, *J*=5.5, 2H), 3.96 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ: 165.02 (d, *J*=3.0), 154.93, 143.88 (d, *J*=11.0), 137.18 (d, *J*=4.5), 135.95 (d, *J*=12.5), 130.09, 128.12 (d, *J*=7.2), 119.85, 117.55 (d, *J*=87.3), 116.54 (d, *J*=14.5), 107.11 (d, *J*=100.3), 70.98, 56.4; ³¹P NMR (162 MHz, CDCl₃) δ: 19.64; *m/z* LRMS (ESI + APCI) found [M-I]⁺ 486.3, C₂₉H₂₉NO₄P⁺ requires 486.2.


Tris(4-methoxyphenyl)(quinolin-4-yl)phosphonium iodide (1n)



Prepared according to general procedure A using 4-iodoquinoline (78 mg, 0.30 mmol), tris(4-methoxyphenyl)phosphane (106 mg, 0.30 mmol), and chloroform (0.6 mL) at room temperature for 39 hours. After purification procedure, the title compound was isolated as a yellow solid (147 mg, 0.24 mmol, 81% yield). mp 112-113 °C; ¹H NMR (400 MHz, CDCl₃) δ = 9.10 (t, *J*=4.1, 1H),


8.23 (d, $J=8.2$, 1H), 7.79 (t, $J=7.7$, 1H), 7.54 – 7.29 (m, 9H), 7.18 (dd, $J=8.9$, 2.6, 6H), 3.88 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ = 165.24 (d, $J=3.0$), 150.10 (d, $J=12.2$), 148.72 (d, $J=6.9$), 136.23 (d, $J=12.3$), 131.72 (d, $J=2.3$), 131.15, 130.11 (d, $J=9.0$), 129.31, 126.59 (d, $J=74.2$), 126.15 (d, $J=2.7$), 125.92 (d, $J=6.4$), 116.95 (d, $J=14.3$), 107.15 (d, $J=98.0$), 56.46; ^{31}P NMR (162 MHz, CDCl_3) δ : 19.60; m/z LRMS (ESI + APCI) found $[\text{M-I}]^+$ 480.2, $\text{C}_{30}\text{H}_{27}\text{NO}_3\text{P}^+$ requires 480.2.

Tris(4-methoxyphenyl)(pyridin-2-yl)phosphonium iodide (1o)



Prepared according to general procedure A using 2-iodopyridine (32 μL , 0.30 mmol), tris(4-methoxyphenyl)phosphane (106 mg, 0.30 mmol), and chloroform (0.6 mL) at 50 $^\circ\text{C}$ for 19 hours. After purification procedure, the title compound was isolated as a yellow solid (114 mg, 0.20 mmol, 63% yield). mp 75-76 $^\circ\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ : 8.96 (dt, $J=4.7$, 1.4, 1H), 8.20 (tdd, $J=7.9$, 5.0, 1.7, 1H), 7.86 (ddt, $J=7.6$, 6.4, 1.2, 1H), 7.73 (dddd, $J=7.8$, 4.7, 2.8, 1.1, 1H), 7.58 (dd, $J=12.3$, 8.9, 6H), 7.21 (dd, $J=9.0$, 2.7, 6H), 3.95 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ : 165.21 (d, $J=2.9$), 152.29 (d, $J=19.4$), 147.10, 145.89, 138.90 (d, $J=10.4$), 136.70 (d, $J=11.8$), 131.73 (d, $J=24.5$), 128.13, 116.53 (d, $J=14.0$), 107.85 (d, $J=97.7$), 56.36; ^{31}P NMR (162 MHz, CDCl_3) δ : 13.80; m/z LRMS (ESI + APCI) found $[\text{M-I}]^+$ 430.2, $\text{C}_{26}\text{H}_{25}\text{NO}_3\text{P}^+$ requires 430.2.


Tris(4-methoxyphenyl)(5-(trifluoromethyl)pyridin-2-yl)phosphonium iodide (1p)



Prepared according to general procedure A using 2-iodo-5-(trifluoromethyl)pyridine (82 mg, 0.30 mmol), tris(4-methoxyphenyl)phosphane (106 mg, 0.30 mmol), and chloroform (0.6 mL) at 80 $^\circ\text{C}$ for 19 hours. After purification procedure, the title compound was isolated as a golden solid (174 mg, 0.28 mmol, 93% yield). mp 87 $^\circ\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ : 9.11 (s, 1H), 8.65 –


8.41 (m, 1H), 8.31 (dd, $J=8.1, 5.9$, 2H), 7.58 (dd, $J=12.4, 8.9$, 6H), 7.21 (dd, $J=9.0, 2.8$, 6H), 3.92 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ : 165.37 (d, $J=3.0$), 150.84 (d, $J=118.7$), 148.36 (dd, $J=19.7, 3.8$), 136.74 (d, $J=12.0$), 136.33 (dd, $J=10.4, 3.6$), 131.98 (d, $J=24.6$), 129.81 (d, $J=31.0$), 122.44 (qd, $J=275.3, 1.7$), 116.67 (d, $J=14.2$), 106.65 (d, $J=98.3$), 56.34; ^{19}F NMR (365 MHz, CDCl_3) δ : -62.82; ^{31}P NMR (162 MHz, CDCl_3) δ : 15.08; m/z LRMS (ESI + APCI) found $[\text{M-I}]^+$ 498.2, $\text{C}_{27}\text{H}_{24}\text{F}_3\text{NO}_3\text{P}^+$ requires 498.1.

(5-chloro-6'-methyl-3-(4-(methylsulfonyl)phenyl)-[2,3'-bipyridin]-4'-yl)tris(4-methoxyphenyl)phosphonium iodide (1q)



Prepared according to general procedure A using 5-chloro-4'-iodo-6'-methyl-3-(4-(methylsulfonyl)phenyl)-2,3'-bipyridine (48 mg, 0.10 mmol), tris(4-methoxyphenyl)phosphane (35 mg, 0.10 mmol), and chloroform (0.2 mL) at room temperature for 34 hours. After purification procedure, the title compound was isolated as a yellow solid (76 mg, 0.09 mmol, 92% yield). mp 180 °C (decomposition); ^1H NMR (400 MHz, CDCl_3) δ : 8.23 (d, $J=6.9$, 1H), 8.10 (d, $J=8.4$, 2H), 7.82 (d, $J=2.3$, 1H), 7.63 (dd, $J=12.3, 9.0$, 6H), 7.51 (d, $J=2.3$, 1H), 7.44 (d, $J=8.5$, 2H), 7.22 (d, $J=16.1$, 1H), 7.14 (dd, $J=9.0, 2.8$, 6H), 3.89 (s, 9H), 3.12 (s, 3H), 2.55 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ : 164.54 (d, $J=3.0$), 160.57 (d, $J=10.9$), 152.82 (d, $J=7.3$), 148.29 (d, $J=2.7$), 146.71, 141.56, 140.92, 138.61, 135.82, 133.76 (d, $J=4.0$), 132.12, 130.65, 130.30, 130.01 (d, $J=43.3$), 128.90, 116.01 (d, $J=14.3$), 109.34 (d, $J=100.2$), 56.36, 44.39, 25.00; ^{31}P NMR (162 MHz, CDCl_3) δ : 23.46; m/z LRMS (ESI + APCI) found $[\text{M-I}]^+$ 709.3, $\text{C}_{39}\text{H}_{35}\text{ClN}_2\text{O}_5\text{PS}^+$ requires 709.2.

(8-chloro-11-(1-(ethoxycarbonyl)piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-4-yl)tris(4-methoxyphenyl)phosphonium iodide (1r)




Prepared according to general procedure A using ethyl 4-(8-chloro-4-iodo-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate (51 mg, 0.10 mmol), tris(4-methoxyphenyl)phosphane (35 mg, 0.10 mmol), and chloroform (0.2 mL) at 50 °C for 19 hours. After purification procedure, the title compound was isolated as a yellow solid (83 mg, 0.1 mmol, 96% yield). mp 153 °C; ^1H NMR (400 MHz, CDCl_3) δ : 8.69 (dd, $J=5.1, 4.2$, 1H), 7.56 (dd, $J=12.5, 8.9$, 6H), 7.28 (dd, $J=9.0, 2.8$, 6H), 7.22 – 7.06 (m, 2H), 7.00 (dd, $J=14.8, 5.1$, 1H), 6.78 (d, $J=2.0$, 1H), 4.13 (q, $J=7.1$, 2H), 3.97 (s, 9H), 3.73 (ddd, $J=22.4, 12.2, 5.8$, 2H), 3.37 (ddd, $J=12.7, 8.2, 4.1$, 2H), 3.28 (ddd, $J=14.8, 11.6, 5.7$, 1H), 2.83 (dt, $J=17.4, 5.2$, 1H), 2.63 (dt, $J=15.0, 4.8$, 1H), 2.53 – 2.32 (m, 2H), 2.21 (s, 1H), 1.72 (ddd, $J=17.2, 11.8, 5.3$, 2H), 1.25 (t, $J=7.1$, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ : 165.34 (d, $J=3.0$), 163.60 (d, $J=8.2$), 155.55, 148.92 (d, $J=11.4$), 139.15, 137.23, 136.80 (d, $J=6.5$), 136.28 (d, $J=12.0$), 133.66, 132.73, 131.66, 130.01, 129.15 (d, $J=83.0$), 127.18 (d, $J=10.3$), 126.58, 117.12 (d, $J=14.2$), 107.04 (d, $J=97.8$), 61.57, 56.54, 44.82, 44.61, 31.01, 30.54, 29.88, 14.7; ^{31}P NMR (162 MHz, CDCl_3) δ : 19.39; m/z LRMS (ESI + APCI) found $[\text{M-I}]^+$ 733.3, $\text{C}_{43}\text{H}_{43}\text{ClN}_2\text{O}_5\text{P}^+$ requires 733.3.


6. References

1. D. D. Perrin, W. L. F. Amereo, Purification of Laboratory Chemicals (Pergamon, ed. 3, 1988).

7. ^1H , ^{13}C , ^{19}F and ^{31}P Spectra




¹³C NMR
CDCl₃, 100 MHz




165.42
165.39
152.00
151.95
150.16
150.06
136.41
136.28
134.76
134.74
130.36
130.28
129.73
128.85
117.09
116.95
106.27
105.28

77.16 CDCl₃

56.51




³¹P NMR
CDCl₃, 162 MHz




1b


-21.08

S22






¹³C NMR
CDCl₃, 100 MHz




1c




-54.14
-54.14


^{19}F NMR
 CD_3CN , 365 MHz




1c




³¹P NMR
CDCl₃, 162 MHz




1c




¹H NMR
CD₃CN, 400 MHz




1d




¹³C NMR
CD₃CN, 100 MHz



1d




³¹P NMR
CDCl₃, 162 MHz




1d

-17.57


S29




¹H NMR
CDCl₃, 400 MHz



1e



¹³C NMR
CDCl₃, 100 MHz




1e


164.83
164.80
159.17
140.97
136.11
135.99
133.93
133.81
127.76
127.68
116.31
116.17
114.37
114.24
108.62
107.63

77.16 CDCl₃

56.20




³¹P NMR
CDCl₃, 162 MHz




1e

— 19.74


S32




¹H NMR
CDCl₃, 400 MHz



1f





¹³C NMR
CDCl₃, 100 MHz

165.17
165.14

152.53
152.44

137.59
137.51
136.20
136.08

126.82
126.00


117.16
117.02

109.82
108.86

77.48
77.16 CDCl₃
76.84

56.51


21.11
21.06



1f

S34


³¹P NMR
CDCl₃, 162 MHz




1f


— 15.33

S35





¹³C NMR
CDCl₃, 100 MHz




1g

165.54
165.51


139.57
139.43
136.50
136.38
135.82
135.03
134.30
129.66
129.58
116.94
116.80
106.77
105.86
105.80
105.75

— 77.16 CDCl₃

— 56.44




³¹P NMR
CDCl₃, 162 MHz





1g

— 20.74

S38









¹³C NMR
CDCl₃, 100 MHz

1h




³¹P NMR
CDCl₃, 162 MHz





1h


-18.33

S41




¹H NMR
CDCl₃, 400 MHz






^{19}F NMR
 CD_3CN , 365 MHz




1i

— -62.76




S44

³¹P NMR
CDCl₃, 162 MHz






— 20.83




S45

¹H NMR
CDCl₃, 400 MHz







¹⁹F NMR
CD₃CN, 365 MHz



-117.35
-117.36
-117.38
-117.39
-117.41
-117.42
-121.53
-121.56
-121.58




³¹P NMR
CDCl₃, 162 MHz





- 20.32


S49



¹H NMR
CDCl₃, 400 MHz



¹³C NMR
CDCl₃, 100 MHz




1k


165.07
165.03
164.90
164.87
162.60
162.57
151.13
151.01
149.79
149.67
136.94
136.82
131.35
130.49
126.95
126.85
116.15
116.01
108.56
107.56

— 77.16 CDCl₃

— 56.21




³¹P NMR
CDCl₃, 162 MHz




1k

-22.97


S52




¹H NMR
CDCl₃, 400 MHz



11



¹³C NMR
CDCl₃, 100 MHz




11


165.57
165.54
154.79
154.73
152.83
152.69
136.67
136.55
134.93
134.06
131.92
131.82
123.02
122.99
117.23
117.09
105.64
104.65

— 77.16 CDCl₃

— 56.56




³¹P NMR
CDCl₃, 162 MHz




11

- 23.14


S55




¹H NMR
CDCl₃, 400 MHz



1m



¹³C NMR
CDCl₃, 100 MHz




1m

165.03
165.00
154.93
143.93
143.82
137.20
137.15
136.01
135.88
130.09
128.15
128.08
119.85
117.99
117.12
116.61
116.47
107.61
106.61


77.16 CDCl₃

70.98


56.44




¹H NMR
CDCl₃, 400 MHz




1n



¹³C NMR
CDCl₃, 100 MHz




1n



S60


³¹P NMR
CDCl₃, 162 MHz





1n

- 19.60


S61



¹H NMR
CDCl₃, 400 MHz



¹³C NMR
CDCl₃, 100 MHz




1o


165.22
165.19
152.38
152.19
147.10
145.89
138.95
138.85
136.76
136.64
131.85
131.60
128.13
116.60
116.46
108.34
107.37

— 77.16 CDCl₃

— 56.36




³¹P NMR
CDCl₃, 162 MHz




1o


-13.80



S64



¹³C NMR
CDCl₃, 100 MHz




1p

165.38
165.35
151.43
150.25
148.48
148.44
148.28
148.24
136.80
136.68
132.10
131.85
129.96
129.65
123.81
121.08
116.74
116.60
107.14
106.16


— 77.16 CDCl₃

— 56.34




S66

^{19}F NMR
CD₃CN, 365 MHz




1p

---62.82



S67


³¹P NMR
CDCl₃, 162 MHz



1p


— 15.08

S68




8.24
8.22
8.11
8.09
7.82
7.81
7.66
7.64
7.63
7.61
7.51
7.51
7.45
7.43
7.26 CDCl3
7.24
7.20
7.16
7.15
7.13
7.13


¹H NMR
CDCl₃, 400 MHz



1q




³¹P NMR
CDCl₃, 162 MHz





1q

— 23.46




S71





³¹P NMR
CDCl₃, 162 MHz



1r

— 19.39

S74

140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -!

f1 (ppm)